NO20055948L - Rensing av HER-2 varianter - Google Patents
Rensing av HER-2 varianterInfo
- Publication number
- NO20055948L NO20055948L NO20055948A NO20055948A NO20055948L NO 20055948 L NO20055948 L NO 20055948L NO 20055948 A NO20055948 A NO 20055948A NO 20055948 A NO20055948 A NO 20055948A NO 20055948 L NO20055948 L NO 20055948L
- Authority
- NO
- Norway
- Prior art keywords
- provides
- chromatography
- variant
- purification
- variants
- Prior art date
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title abstract 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title abstract 2
- 238000000746 purification Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 3
- 238000005571 anion exchange chromatography Methods 0.000 abstract 2
- 238000001597 immobilized metal affinity chromatography Methods 0.000 abstract 2
- 238000001542 size-exclusion chromatography Methods 0.000 abstract 2
- 241000238631 Hexapoda Species 0.000 abstract 1
- 238000004113 cell culture Methods 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
Abstract
Foreliggende oppfinnelse skaffer til veie en ny metode for rensing av EGFR famihe proteiner oppnådd fra kulturer av insektceller. Fremgangsmåten omfatter følgende trinn med a) diafiltrering og utbytting av dyrkningsmediet med buffer, b) immobilisert metall affinitet kromatografi (IMAC), c) størrelse eksklusjons kromatografi (SEC), og d) anionbytter kromatografi (AIE). Fremgangsmåten skaffer også til veie en immunogen variant av HER-2 proteinet for hvilken renseprosessen har vært særlig tilpasset, så vel som måter for fremstilling av varianten.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US48231503P | 2003-06-25 | 2003-06-25 | |
DKPA200300954 | 2003-06-25 | ||
PCT/DK2004/000451 WO2004113377A1 (en) | 2003-06-25 | 2004-06-24 | Purification of her-2 variants |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20055948L true NO20055948L (no) | 2005-12-14 |
Family
ID=33542436
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20055948A NO20055948L (no) | 2003-06-25 | 2005-12-14 | Rensing av HER-2 varianter |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP1641819B1 (no) |
JP (1) | JP4579912B2 (no) |
AT (1) | ATE429447T1 (no) |
AU (1) | AU2004249362B2 (no) |
CA (1) | CA2530233C (no) |
DE (1) | DE602004020769D1 (no) |
DK (1) | DK1641819T3 (no) |
ES (1) | ES2325584T3 (no) |
MX (1) | MXPA05013389A (no) |
NO (1) | NO20055948L (no) |
NZ (1) | NZ544017A (no) |
WO (1) | WO2004113377A1 (no) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20060033870A (ko) | 2003-06-25 | 2006-04-20 | 파멕사 에이/에스 | Her-2 변이체의 정제 |
WO2006102901A2 (en) * | 2005-03-31 | 2006-10-05 | Pharmexa A/S | Immunogenic egfr peptides comprising foreign t cell stimulating epitope |
EP2073837B1 (en) * | 2006-10-06 | 2014-06-25 | Bavarian Nordic Inc. | Recombinant modified vaccinia ankara virus encoding a her-2 antigen in combination with a taxane for use in treating cancer |
EP4211468A4 (en) * | 2020-09-11 | 2024-10-09 | Glympse Bio Inc | DETECTION OF EX VIVO PROTEASE ACTIVITY FOR DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT OF DISEASES |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
JP2002526419A (ja) | 1998-10-05 | 2002-08-20 | ファーメクサ エイ/エス | 治療上のワクチン注射のための新規な方法 |
CN1201004C (zh) * | 1999-01-29 | 2005-05-11 | 考丽克萨有限公司 | HER-2/neu融合蛋白 |
WO2003087338A2 (en) * | 2002-04-11 | 2003-10-23 | Amgen, Inc. | Her-2 receptor tyrosine kinase molecules and uses thereof |
-
2004
- 2004-06-24 JP JP2006515732A patent/JP4579912B2/ja not_active Expired - Fee Related
- 2004-06-24 EP EP04738948A patent/EP1641819B1/en not_active Expired - Lifetime
- 2004-06-24 MX MXPA05013389A patent/MXPA05013389A/es unknown
- 2004-06-24 ES ES04738948T patent/ES2325584T3/es not_active Expired - Lifetime
- 2004-06-24 DK DK04738948T patent/DK1641819T3/da active
- 2004-06-24 WO PCT/DK2004/000451 patent/WO2004113377A1/en active Application Filing
- 2004-06-24 NZ NZ544017A patent/NZ544017A/en not_active IP Right Cessation
- 2004-06-24 AT AT04738948T patent/ATE429447T1/de active
- 2004-06-24 EP EP09005519A patent/EP2090586A1/en not_active Withdrawn
- 2004-06-24 CA CA2530233A patent/CA2530233C/en not_active Expired - Fee Related
- 2004-06-24 DE DE602004020769T patent/DE602004020769D1/de not_active Expired - Lifetime
- 2004-06-24 AU AU2004249362A patent/AU2004249362B2/en not_active Ceased
-
2005
- 2005-12-14 NO NO20055948A patent/NO20055948L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2007523615A (ja) | 2007-08-23 |
CA2530233A1 (en) | 2004-12-29 |
EP1641819B1 (en) | 2009-04-22 |
DK1641819T3 (da) | 2009-08-03 |
NZ544017A (en) | 2008-04-30 |
JP4579912B2 (ja) | 2010-11-10 |
MXPA05013389A (es) | 2006-03-17 |
EP1641819A1 (en) | 2006-04-05 |
ATE429447T1 (de) | 2009-05-15 |
EP2090586A1 (en) | 2009-08-19 |
AU2004249362B2 (en) | 2011-08-25 |
CA2530233C (en) | 2012-09-11 |
AU2004249362A1 (en) | 2004-12-29 |
WO2004113377A1 (en) | 2004-12-29 |
DE602004020769D1 (de) | 2009-06-04 |
ES2325584T3 (es) | 2009-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20063478L (no) | Noytraliserende epitopebasert vekstfremmende vaksine | |
EP1568710A3 (en) | Antibody purification method | |
WO2008013454A3 (en) | Immunogenic compounds and protein mimics | |
DK1553975T3 (da) | Optimerede Fc-varianter og fremgangsmåder til generering heraf. | |
NO20071432L (no) | Fremgangsmate for konsentrasjon av antistoffer of terapeutiske produkter derav. | |
EA200970263A1 (ru) | Полностью человеческая высокопродуктивная система получения усовершенствованных антител и белков | |
WO2005016968A3 (en) | Reducing protein a leaching during protein a affinity chromatography | |
WO2006041934A3 (en) | Methods and compositions for improving recombinant protein production | |
WO2005118620A3 (en) | Methods for preparing internally constraied peptides and peptidomimetics | |
WO2003062375A3 (en) | Stabilizing polypeptides which have been exposed to urea | |
ATE521627T1 (de) | Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins | |
MX2009012451A (es) | Plantas con rasgos mejorados relacionados con el rendimiento y un metodo para producirlas. | |
IL176522A0 (en) | Universal amplification of fragmented rna | |
NO20063278L (no) | Hurtigfremstilling av nukleinsyrer ved enzymatisk fordoyelse | |
WO2007130535A3 (en) | Novel protein fusion/tag technology | |
AR048651A1 (es) | Proceso de amonolisis enzimatica para preparacion de compuestos intermediarios para inhibidores de dipeptidilo peptidasa iv | |
NO20055948L (no) | Rensing av HER-2 varianter | |
NO20075911L (no) | Genetisk modifisert mikroorganisme og fremgangsmate for fremstilling av makrolidforbindelser ved anvendelse av mikroorganismen | |
EA200600102A1 (ru) | Очистка вариантов her-2 | |
ATE386823T1 (de) | Marker-unterstützte rinderauswahl für verbesserte milchzusammensetzung | |
TW200722435A (en) | Purification of proteins with cationic surfactant | |
DK1639110T3 (da) | Rajgræspollenspecifikke promotorer og ekspressionskonstructer | |
DE50002865D1 (de) | Verfahren zur herstellung von benzofuranonoximen | |
WO2003064597A3 (en) | Aggrecanase molecules | |
ATE381576T1 (de) | Verfahren zur aufreinigung eines n-terminalen fragments des hepatozytenwachstumsfaktors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |